Wellington Management Group LLP Increases Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Wellington Management Group LLP raised its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 3.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,586,605 shares of the company's stock after buying an additional 104,500 shares during the period. Wellington Management Group LLP owned about 4.73% of Nurix Therapeutics worth $67,572,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. US Bancorp DE boosted its position in Nurix Therapeutics by 144.7% during the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after buying an additional 842 shares during the period. GF Fund Management CO. LTD. purchased a new stake in Nurix Therapeutics during the 4th quarter valued at $28,000. Aquatic Capital Management LLC purchased a new stake in Nurix Therapeutics during the 4th quarter valued at $87,000. Summit Investment Advisors Inc. boosted its position in Nurix Therapeutics by 13.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock valued at $138,000 after buying an additional 877 shares during the period. Finally, BNP Paribas Financial Markets purchased a new stake in Nurix Therapeutics during the 4th quarter valued at $164,000.

Nurix Therapeutics Trading Up 14.2%

NASDAQ:NRIX traded up $1.51 on Monday, reaching $12.14. 2,404,135 shares of the stock traded hands, compared to its average volume of 877,809. The company has a market capitalization of $925.51 million, a price-to-earnings ratio of -4.20 and a beta of 2.23. Nurix Therapeutics, Inc. has a 12 month low of $8.18 and a 12 month high of $29.56. The company's fifty day simple moving average is $10.34 and its 200 day simple moving average is $15.57.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. The business had revenue of $18.45 million during the quarter, compared to analyst estimates of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same period last year, the business earned ($0.76) EPS. Equities analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Analysts Set New Price Targets

NRIX has been the subject of several analyst reports. Wall Street Zen cut shares of Nurix Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Leerink Partnrs upgraded shares of Nurix Therapeutics to a "hold" rating in a report on Monday, March 17th. Needham & Company LLC restated a "buy" rating and issued a $27.00 price objective on shares of Nurix Therapeutics in a report on Tuesday, April 29th. Leerink Partners began coverage on shares of Nurix Therapeutics in a report on Monday, March 17th. They issued a "market perform" rating and a $16.00 price objective for the company. Finally, Wells Fargo & Company decreased their price objective on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a report on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $30.44.

Insider Buying and Selling at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 6,198 shares of the firm's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $11.33, for a total transaction of $70,223.34. Following the sale, the chief financial officer now owns 33,724 shares of the company's stock, valued at $382,092.92. This trade represents a 15.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gwenn Hansen sold 3,377 shares of the firm's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the sale, the insider now directly owns 61,516 shares in the company, valued at approximately $707,434. The trade was a 5.20% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 12,013 shares of company stock worth $137,096. 7.40% of the stock is owned by corporate insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.